According to an editorial, in recent years, the evidence for the tremendous burden of hidradenitis suppurativa (HS) has been mounting and there are now retrospective data from large numbers of patients with HS extending knowledge about comorbidity burden as highlighted in this and two other recent JAMA Dermatology publications. These data support the prevalence of comorbid diabetes in HS while also revealing previously unrecognized associated life-threatening chronic comorbidities that are key to shaping assessment and treatment of this patient population. It notes that the guidance on how to translate these findings into clinical practice is lacking.